These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37218899)

  • 1. Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague.
    Biryukov SS; Wu H; Dankmeyer JL; Rill NO; Klimko CP; Egland KA; Shoe JL; Hunter M; Fetterer DP; Qiu J; Davies ML; Bausch CL; Sullivan EJ; Luke T; Cote CK
    Antibodies (Basel); 2023 May; 12(2):. PubMed ID: 37218899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
    D'Arco C; McCormick AA; Arnaboldi PM
    Vaccine; 2021 Mar; 39(9):1435-1444. PubMed ID: 33531196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Protection Against
    Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
    Front Immunol; 2022; 13():793382. PubMed ID: 35154110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
    Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection Induced by Oral Vaccination with a Recombinant
    Majumder S; Olson RM; Singh A; Wang X; Li P; Kittana H; Anderson PE; Anderson DM; Sun W
    Infect Immun; 2022 Aug; 90(8):e0016522. PubMed ID: 35900096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
    Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
    Yang X; Hinnebusch BJ; Trunkle T; Bosio CM; Suo Z; Tighe M; Harmsen A; Becker T; Crist K; Walters N; Avci R; Pascual DW
    J Immunol; 2007 Jan; 178(2):1059-67. PubMed ID: 17202369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
    Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
    Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
    Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
    mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody Opsonization Enhances Early Interactions between Yersinia pestis and Neutrophils in the Skin and Draining Lymph Node in a Mouse Model of Bubonic Plague.
    Shannon JG; Hinnebusch BJ
    Infect Immun; 2020 Dec; 89(1):. PubMed ID: 33077628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
    Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
    mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
    Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
    Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.
    Tao P; Mahalingam M; Kirtley ML; van Lier CJ; Sha J; Yeager LA; Chopra AK; Rao VB
    PLoS Pathog; 2013; 9(7):e1003495. PubMed ID: 23853602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
    Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
    Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW
    Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
    Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
    Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.
    Heath DG; Anderson GW; Mauro JM; Welkos SL; Andrews GP; Adamovicz J; Friedlander AM
    Vaccine; 1998 Jul; 16(11-12):1131-7. PubMed ID: 9682370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.